These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10342571)

  • 1. Serum CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Jalkanen S
    Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
    Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
    Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
    Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
    Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
    Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children.
    Elli M; Dagdemir A; Bozkurt C; Pinarli FG; Duzgun A; Ozmen ZC; Ertem U; Acar S
    Bratisl Lek Listy; 2012; 113(9):534-8. PubMed ID: 22979908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
    Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
    Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
    Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K
    Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
    Sasaki K; Niitsu N
    Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54).
    Horst E; Meijer CJ; Radaszkiewicz T; Ossekoppele GJ; Van Krieken JH; Pals ST
    Leukemia; 1990 Aug; 4(8):595-9. PubMed ID: 1974938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
    Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
    Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression.
    Khaldoyanidi S; Achtnich M; Hehlmann R; Zöller M
    Leuk Res; 1996 Oct; 20(10):839-51. PubMed ID: 8960109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression of CD44, PCNA, vWF: Ag in non-Hodgkin's lymphoma and its relationship with the grade of malignancy].
    Li W; Li Y; Han Y
    Zhonghua Xue Ye Xue Za Zhi; 1998 Nov; 19(11):569-72. PubMed ID: 11263339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of serum CD44 measurement in malignant lymphoma.
    Fukuda Y
    Kurume Med J; 2001; 48(1):65-9. PubMed ID: 11402623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
    De Rossi G; Marroni P; Paganuzzi M; Mauro FR; Tenca C; Zarcone D; Velardi A; Molica S; Grossi CE
    Leukemia; 1997 Jan; 11(1):134-41. PubMed ID: 9001429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas.
    Martin P
    Leuk Lymphoma; 2012 Jan; 53(1):1-2. PubMed ID: 22035419
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
    Khalifa KA; Alkilani AA; Ismail H; Soliman MA
    J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma.
    Navarro JT; Ribera JM; Vaquero M; Pastor MC; Oriol A; Romeu J; Batlle M; Millá F; Feliu E
    AIDS; 2000 Jul; 14(10):1460-1. PubMed ID: 10930167
    [No Abstract]   [Full Text] [Related]  

  • 19. Origin and function of circulating CD44 in non-Hodgkin's lymphoma.
    Ristämaki R; Joensuu H; Grön-Virta K; Salmi M; Jalkanen S
    J Immunol; 1997 Mar; 158(6):3000-8. PubMed ID: 9058839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
    Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
    Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.